TWI439459B - 作為JANUS激酶抑制劑之吡咯并〔２，３-ｂ〕吡啶-４-基-胺及吡咯并〔２，３-ｂ〕嘧啶-４-基-胺 - Google Patents

Info

Publication number

TWI439459B

TWI439459B TW094145677A TW94145677A TWI439459B TW I439459 B TWI439459 B TW I439459B TW 094145677 A TW094145677 A TW 094145677A TW 94145677 A TW94145677 A TW 94145677A TW I439459 B TWI439459 B TW I439459B

Authority

TW

Taiwan

Prior art keywords

methyl

alkyl

pyridin

pyrrole

group

Prior art date

2004-12-22

Links

• Espacenet
• Global Dossier
• Discuss

• 229940122245 Janus kinase inhibitor Drugs 0.000 title description 9
• RCWISWVYKNLXHC-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridin-4-amine Chemical class NC1=CC=NC2=C1C=CN2 RCWISWVYKNLXHC-UHFFFAOYSA-N 0.000 title 1
• 125000000217 alkyl group Chemical group 0.000 claims description 457
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 195
• 150000001875 compounds Chemical class 0.000 claims description 157
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 120
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 102
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 101
• 125000003118 aryl group Chemical group 0.000 claims description 97
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 92
• 125000001072 heteroaryl group Chemical group 0.000 claims description 91
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 73
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 66
• 102000015617 Janus Kinases Human genes 0.000 claims description 64
• 108010024121 Janus Kinases Proteins 0.000 claims description 64
• 125000005843 halogen group Chemical group 0.000 claims description 58
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
• 239000000203 mixture Substances 0.000 claims description 54
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 50
• 201000010099 disease Diseases 0.000 claims description 50
• 125000001424 substituent group Chemical group 0.000 claims description 49
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 48
• 125000000304 alkynyl group Chemical group 0.000 claims description 47
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 40
• -1 piperidine-1-yl Indoleamine Chemical compound 0.000 claims description 40
• 150000003839 salts Chemical class 0.000 claims description 40
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 39
• 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 39
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 38
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 38
• 125000003545 alkoxy group Chemical group 0.000 claims description 35
• 125000002947 alkylene group Chemical group 0.000 claims description 31
• 229910052799 carbon Inorganic materials 0.000 claims description 31
• 125000003342 alkenyl group Chemical group 0.000 claims description 27
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 25
• 230000000694 effects Effects 0.000 claims description 23
• 108091000080 Phosphotransferase Proteins 0.000 claims description 22
• 229910052739 hydrogen Inorganic materials 0.000 claims description 22
• 102000020233 phosphotransferase Human genes 0.000 claims description 22
• 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 21
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 21
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 18
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 17
• 201000004681 Psoriasis Diseases 0.000 claims description 16
• 229910052717 sulfur Inorganic materials 0.000 claims description 16
• 125000004432 carbon atom Chemical group C* 0.000 claims description 15
• 229910052760 oxygen Inorganic materials 0.000 claims description 15
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 11
• 206010028980 Neoplasm Diseases 0.000 claims description 11
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 11
• 239000008194 pharmaceutical composition Substances 0.000 claims description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
• 201000011510 cancer Diseases 0.000 claims description 10
• 239000003814 drug Substances 0.000 claims description 10
• 208000034578 Multiple myelomas Diseases 0.000 claims description 9
• 150000001335 aliphatic alkanes Chemical class 0.000 claims description 9
• 125000004429 atom Chemical group 0.000 claims description 9
• 125000005842 heteroatom Chemical group 0.000 claims description 9
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 8
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 8
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
• 239000002253 acid Substances 0.000 claims description 8
• 125000002252 acyl group Chemical group 0.000 claims description 8
• 229910052757 nitrogen Inorganic materials 0.000 claims description 8
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 8
• 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 7
• 125000004104 aryloxy group Chemical group 0.000 claims description 7
• 238000011200 topical administration Methods 0.000 claims description 7
• 208000023275 Autoimmune disease Diseases 0.000 claims description 6
• 230000001363 autoimmune Effects 0.000 claims description 6
• 125000000623 heterocyclic group Chemical group 0.000 claims description 6
• 230000002401 inhibitory effect Effects 0.000 claims description 6
• 238000002360 preparation method Methods 0.000 claims description 6
• MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 claims description 5
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 239000001301 oxygen Substances 0.000 claims description 5
• 125000003386 piperidinyl group Chemical group 0.000 claims description 5
• 239000011593 sulfur Substances 0.000 claims description 5
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
• 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
• 241000701806 Human papillomavirus Species 0.000 claims description 4
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
• 208000024908 graft versus host disease Diseases 0.000 claims description 4
• 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
• 208000032839 leukemia Diseases 0.000 claims description 4
• 239000006210 lotion Substances 0.000 claims description 4
• 239000002674 ointment Substances 0.000 claims description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 3
• 208000011231 Crohn disease Diseases 0.000 claims description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
• 229940124639 Selective inhibitor Drugs 0.000 claims description 3
• 239000006071 cream Substances 0.000 claims description 3
• 239000000499 gel Substances 0.000 claims description 3
• 201000006417 multiple sclerosis Diseases 0.000 claims description 3
• 230000003612 virological effect Effects 0.000 claims description 3
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 2
• 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 claims description 2
• 102100037813 Focal adhesion kinase 1 Human genes 0.000 claims description 2
• 208000005176 Hepatitis C Diseases 0.000 claims description 2
• 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 2
• 108010000837 Janus Kinase 1 Proteins 0.000 claims description 2
• 108010019437 Janus Kinase 2 Proteins 0.000 claims description 2
• 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
• 206010025323 Lymphomas Diseases 0.000 claims description 2
• 206010060862 Prostate cancer Diseases 0.000 claims description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
• 125000004423 acyloxy group Chemical group 0.000 claims description 2
• 125000003282 alkyl amino group Chemical group 0.000 claims description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
• 239000007933 dermal patch Substances 0.000 claims description 2
• 208000002672 hepatitis B Diseases 0.000 claims description 2
• 150000002430 hydrocarbons Chemical class 0.000 claims description 2
• 206010025135 lupus erythematosus Diseases 0.000 claims description 2
• 125000004076 pyridyl group Chemical group 0.000 claims description 2
• 125000001544 thienyl group Chemical group 0.000 claims description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
• JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims 22
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 21
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 19
• KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 3
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
• 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 2
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
• ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 claims 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
• 239000004215 Carbon black (E152) Substances 0.000 claims 1
• 102000006503 Janus Kinase 2 Human genes 0.000 claims 1
• 208000024799 Thyroid disease Diseases 0.000 claims 1
• ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 1
• 150000001345 alkine derivatives Chemical class 0.000 claims 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 1
• 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 1
• 229930195733 hydrocarbon Natural products 0.000 claims 1
• 150000002576 ketones Chemical class 0.000 claims 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
• YKFLJYAKACCWMH-UHFFFAOYSA-N methyl piperidine-1-carboxylate Chemical compound COC(=O)N1CCCCC1 YKFLJYAKACCWMH-UHFFFAOYSA-N 0.000 claims 1
• 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
• QUUYRYYUKNNNNS-UHFFFAOYSA-N piperidine-1-carboximidamide Chemical compound NC(=N)N1CCCCC1 QUUYRYYUKNNNNS-UHFFFAOYSA-N 0.000 claims 1
• ZGNXATVKGIJQGC-UHFFFAOYSA-N piperidine-3-carbonitrile Chemical compound N#CC1CCCNC1 ZGNXATVKGIJQGC-UHFFFAOYSA-N 0.000 claims 1
• FSDNTQSJGHSJBG-UHFFFAOYSA-N piperidine-4-carbonitrile Chemical compound N#CC1CCNCC1 FSDNTQSJGHSJBG-UHFFFAOYSA-N 0.000 claims 1
• 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
• SBYMJCKWCIIWCK-UHFFFAOYSA-N pyrrolidine-3,4-dicarbonitrile Chemical compound N1CC(C(C1)C#N)C#N SBYMJCKWCIIWCK-UHFFFAOYSA-N 0.000 claims 1
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
• 238000000034 method Methods 0.000 description 25
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 24
• 239000000243 solution Substances 0.000 description 24
• 108010019421 Janus Kinase 3 Proteins 0.000 description 23
• 125000004450 alkenylene group Chemical group 0.000 description 22
• 210000004027 cell Anatomy 0.000 description 22
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 20
• 238000011282 treatment Methods 0.000 description 19
• 102000004127 Cytokines Human genes 0.000 description 16
• 108090000695 Cytokines Proteins 0.000 description 16
• 239000007787 solid Substances 0.000 description 15
• 238000012360 testing method Methods 0.000 description 15
• 238000006243 chemical reaction Methods 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 12
• 238000005481 NMR spectroscopy Methods 0.000 description 11
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 11
• 230000028993 immune response Effects 0.000 description 11
• 230000005951 type IV hypersensitivity Effects 0.000 description 11
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 11
• 230000005764 inhibitory process Effects 0.000 description 10
• 239000000546 pharmaceutical excipient Substances 0.000 description 10
• 239000000651 prodrug Substances 0.000 description 10
• 229940002612 prodrug Drugs 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
• 239000002552 dosage form Substances 0.000 description 9
• 241000699670 Mus sp. Species 0.000 description 8
• 239000004480 active ingredient Substances 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 230000026731 phosphorylation Effects 0.000 description 8
• 238000006366 phosphorylation reaction Methods 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 208000010201 Exanthema Diseases 0.000 description 7
• 102000042838 JAK family Human genes 0.000 description 7
• 108091082332 JAK family Proteins 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 206010057190 Respiratory tract infections Diseases 0.000 description 7
• 206010070834 Sensitisation Diseases 0.000 description 7
• 210000001744 T-lymphocyte Anatomy 0.000 description 7
• 230000004913 activation Effects 0.000 description 7
• 201000005884 exanthem Diseases 0.000 description 7
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• 206010037844 rash Diseases 0.000 description 7
• 239000011541 reaction mixture Substances 0.000 description 7
• 230000008313 sensitization Effects 0.000 description 7
• 230000019491 signal transduction Effects 0.000 description 7
• 210000003491 skin Anatomy 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• 102000004889 Interleukin-6 Human genes 0.000 description 6
• 108090001005 Interleukin-6 Proteins 0.000 description 6
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 208000017733 acquired polycythemia vera Diseases 0.000 description 6
• 150000001412 amines Chemical class 0.000 description 6
• 125000003277 amino group Chemical group 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 208000006673 asthma Diseases 0.000 description 6
• 230000035772 mutation Effects 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 208000037244 polycythemia vera Diseases 0.000 description 6
• 125000006239 protecting group Chemical group 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 206010012442 Dermatitis contact Diseases 0.000 description 5
• 206010012735 Diarrhoea Diseases 0.000 description 5
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 5
• 235000019502 Orange oil Nutrition 0.000 description 5
• 208000010668 atopic eczema Diseases 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 208000010247 contact dermatitis Diseases 0.000 description 5
• 102000003675 cytokine receptors Human genes 0.000 description 5
• 108010057085 cytokine receptors Proteins 0.000 description 5
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
• 229960003957 dexamethasone Drugs 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 229940100601 interleukin-6 Drugs 0.000 description 5
• 239000010502 orange oil Substances 0.000 description 5
• 239000012074 organic phase Substances 0.000 description 5
• 239000008177 pharmaceutical agent Substances 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 230000004163 JAK-STAT signaling pathway Effects 0.000 description 4
• 101150069380 JAK3 gene Proteins 0.000 description 4
• 108091054455 MAP kinase family Proteins 0.000 description 4
• 102000043136 MAP kinase family Human genes 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 208000014767 Myeloproliferative disease Diseases 0.000 description 4
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 4
• 201000006966 adult T-cell leukemia Diseases 0.000 description 4
• 230000000172 allergic effect Effects 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 230000028709 inflammatory response Effects 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000007937 lozenge Substances 0.000 description 4
• 125000002950 monocyclic group Chemical group 0.000 description 4
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
• 238000007911 parenteral administration Methods 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 125000003367 polycyclic group Chemical group 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 239000007921 spray Substances 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000007910 systemic administration Methods 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 101150013553 CD40 gene Proteins 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 206010014025 Ear swelling Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• 208000029462 Immunodeficiency disease Diseases 0.000 description 3
• 102000013462 Interleukin-12 Human genes 0.000 description 3
• 108010065805 Interleukin-12 Proteins 0.000 description 3
• 101150009057 JAK2 gene Proteins 0.000 description 3
• 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 3
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
• 206010040880 Skin irritation Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 230000005754 cellular signaling Effects 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 125000004438 haloalkoxy group Chemical group 0.000 description 3
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 238000000099 in vitro assay Methods 0.000 description 3
• 230000008595 infiltration Effects 0.000 description 3
• 238000001764 infiltration Methods 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 239000012044 organic layer Substances 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000008054 signal transmission Effects 0.000 description 3
• 230000036556 skin irritation Effects 0.000 description 3
• 231100000475 skin irritation Toxicity 0.000 description 3
• 238000010189 synthetic method Methods 0.000 description 3
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 3
• KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 102000008986 Janus Human genes 0.000 description 2
• 108050000950 Janus Proteins 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 102000005886 STAT4 Transcription Factor Human genes 0.000 description 2
• 108010019992 STAT4 Transcription Factor Proteins 0.000 description 2
• 108010011005 STAT6 Transcription Factor Proteins 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 2
• 206010070835 Skin sensitisation Diseases 0.000 description 2
• 201000008736 Systemic mastocytosis Diseases 0.000 description 2
• 210000004241 Th2 cell Anatomy 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000006242 amine protecting group Chemical group 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 239000012043 crude product Substances 0.000 description 2
• MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 239000012055 enteric layer Substances 0.000 description 2
• 230000010437 erythropoiesis Effects 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 239000013022 formulation composition Substances 0.000 description 2
• 230000014509 gene expression Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 230000007813 immunodeficiency Effects 0.000 description 2
• 238000002991 immunohistochemical analysis Methods 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
• 229960001924 melphalan Drugs 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 230000001400 myeloablative effect Effects 0.000 description 2
• 206010028537 myelofibrosis Diseases 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
• 150000007523 nucleic acids Chemical group 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 229940124531 pharmaceutical excipient Drugs 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
• 238000001953 recrystallisation Methods 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 231100000370 skin sensitisation Toxicity 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• NVKDDQBZODSEIN-OCCSQVGLSA-N (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine Chemical compound C1C[C@@H](C)[C@@H](NC)CN1CC1=CC=CC=C1 NVKDDQBZODSEIN-OCCSQVGLSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
• 150000004057 1,4-benzoquinones Chemical class 0.000 description 1
• XYFAEHZVQWTOPH-UHFFFAOYSA-N 1-benzyl-n-methylpiperidin-3-amine Chemical compound C1C(NC)CCCN1CC1=CC=CC=C1 XYFAEHZVQWTOPH-UHFFFAOYSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• WIFCKLPZYYALGY-UHFFFAOYSA-N 1h-pyrrole-2,3-dione Chemical compound O=C1NC=CC1=O WIFCKLPZYYALGY-UHFFFAOYSA-N 0.000 description 1
• MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
• CSJCEQXZVMIHRX-UHFFFAOYSA-N 2,3-dibenzyl-2,3-dihydroxybutanedioic acid Chemical compound C=1C=CC=CC=1CC(O)(C(O)=O)C(O)(C(=O)O)CC1=CC=CC=C1 CSJCEQXZVMIHRX-UHFFFAOYSA-N 0.000 description 1
• CLGVOZPMWDEZCD-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(sulfanyl)butanedioic acid Chemical compound SC(C(C(=O)O)(O)S)(O)C(=O)O CLGVOZPMWDEZCD-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 1
• DETXZQGDWUJKMO-UHFFFAOYSA-N 2-hydroxymethanesulfonic acid Chemical compound OCS(O)(=O)=O DETXZQGDWUJKMO-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• UUUOHRSINXUJKX-UHFFFAOYSA-N 3-chloro-1h-pyrrole Chemical compound ClC=1C=CNC=1 UUUOHRSINXUJKX-UHFFFAOYSA-N 0.000 description 1
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 206010027654 Allergic conditions Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• QASXKPHVAIWJGK-UHFFFAOYSA-N C(C1=CC=CC=C1)=C1C(C(C2=CC=CC=C2C1=O)=O)=N Chemical compound C(C1=CC=CC=C1)=C1C(C(C2=CC=CC=C2C1=O)=O)=N QASXKPHVAIWJGK-UHFFFAOYSA-N 0.000 description 1
• PKCBATWOWIDSRJ-UHFFFAOYSA-N C1COCCO1.O=C1C=CC(=O)C=C1 Chemical compound C1COCCO1.O=C1C=CC(=O)C=C1 PKCBATWOWIDSRJ-UHFFFAOYSA-N 0.000 description 1
• 208000005024 Castleman disease Diseases 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 241000723346 Cinnamomum camphora Species 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 1
• 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
• 210000004128 D cell Anatomy 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000004262 Food Hypersensitivity Diseases 0.000 description 1
• 206010016946 Food allergy Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 101150106931 IFNG gene Proteins 0.000 description 1
• 238000004566 IR spectroscopy Methods 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000003812 Interleukin-15 Human genes 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 108090000171 Interleukin-18 Proteins 0.000 description 1
• 102100039898 Interleukin-18 Human genes 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000013264 Interleukin-23 Human genes 0.000 description 1
• 108010065637 Interleukin-23 Proteins 0.000 description 1
• 102000000704 Interleukin-7 Human genes 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 230000035986 JAK-STAT signaling Effects 0.000 description 1
• 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
• FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• ITWGHFBDRJHWOS-UHFFFAOYSA-N O1COC=C1.C1(CC(CC=C1)=O)=O Chemical compound O1COC=C1.C1(CC(CC=C1)=O)=O ITWGHFBDRJHWOS-UHFFFAOYSA-N 0.000 description 1
• HJXROMUYQSVDQM-UHFFFAOYSA-N OC1(CC=CC=C1)NN Chemical compound OC1(CC=CC=C1)NN HJXROMUYQSVDQM-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 208000031951 Primary immunodeficiency Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical group [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010065899 Tracheal inflammation Diseases 0.000 description 1
• 206010044302 Tracheitis Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000000887 Transcription factor STAT Human genes 0.000 description 1
• 108050007918 Transcription factor STAT Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• MOFOSIONNMTXNL-UHFFFAOYSA-N [N+](=O)([O-])C=1C(=C(C=CC1)C(C(=O)O)(O)CC1=CC=CC=C1)[N+](=O)[O-] Chemical compound [N+](=O)([O-])C=1C(=C(C=CC1)C(C(=O)O)(O)CC1=CC=CC=C1)[N+](=O)[O-] MOFOSIONNMTXNL-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 229940081735 acetylcellulose Drugs 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 125000005333 aroyloxy group Chemical group 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000005410 aryl sulfonium group Chemical group 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• VBILKJAUJJRAPR-UHFFFAOYSA-N butylphosphane;toluene Chemical compound CCCCP.CC1=CC=CC=C1 VBILKJAUJJRAPR-UHFFFAOYSA-N 0.000 description 1
• FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
• 239000001354 calcium citrate Substances 0.000 description 1
• 229960004256 calcium citrate Drugs 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 229960001714 calcium phosphate Drugs 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 229960000846 camphor Drugs 0.000 description 1
• 229930008380 camphor Natural products 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 235000013877 carbamide Nutrition 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 230000001427 coherent effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 230000006552 constitutive activation Effects 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
• SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 125000006612 decyloxy group Chemical group 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000004041 dendritic cell maturation Effects 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 230000009025 developmental regulation Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 229960002179 ephedrine Drugs 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 229940082789 erbitux Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000020375 flavoured syrup Nutrition 0.000 description 1
• 238000012757 fluorescence staining Methods 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 238000001215 fluorescent labelling Methods 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000020932 food allergy Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000011194 food seasoning agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 229940014259 gelatin Drugs 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 230000002140 halogenating effect Effects 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000004404 heteroalkyl group Chemical group 0.000 description 1
• 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 238000003709 image segmentation Methods 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000007365 immunoregulation Effects 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000011344 liquid material Substances 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 239000012931 lyophilized formulation Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 238000000691 measurement method Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• XOPUORAQCYGJPT-UHFFFAOYSA-N methanesulfonic acid;hydrochloride Chemical compound Cl.CS(O)(=O)=O XOPUORAQCYGJPT-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 229940050176 methyl chloride Drugs 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 229960002221 methylephedrine Drugs 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 238000003801 milling Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000009984 peri-natal effect Effects 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 230000009038 pharmacological inhibition Effects 0.000 description 1
• 125000005561 phenanthryl group Chemical group 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 150000004031 phenylhydrazines Chemical class 0.000 description 1
• DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
• 229960000395 phenylpropanolamine Drugs 0.000 description 1
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 201000003725 primary thrombocytopenia Diseases 0.000 description 1
• 230000007112 pro inflammatory response Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 238000012342 propidium iodide staining Methods 0.000 description 1
• FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• ADRDEXBBJTUCND-UHFFFAOYSA-N pyrrolizidine Chemical compound C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000025053 regulation of cell proliferation Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000002390 rotary evaporation Methods 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 239000012056 semi-solid material Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 238000007711 solidification Methods 0.000 description 1
• 230000008023 solidification Effects 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 229910052712 strontium Inorganic materials 0.000 description 1
• CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 150000003505 terpenes Chemical class 0.000 description 1
• 235000007586 terpenes Nutrition 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 108091006106 transcriptional activators Proteins 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 235000013337 tricalcium citrate Nutrition 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical group NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 238000009827 uniform distribution Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 229940099039 velcade Drugs 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1